BioCentury | Jul 3, 2020
Deals

July 2 Quick Takes: Novartis to ante up $678M in settlement; plus Zai, Neoleukin, Base Genomics, Sarepta-Hansa, Dr. Reddy-Fujifilm

Novartis to pay $678M in kickbacks settlement  Novartis AG (NYSE:NVS; SIX:NOVN) will pay $678 million and, under a corporate integrity agreement, conduct its speaker programs virtually for the next five years after the pharma reached...
BioCentury | Jun 20, 2020
Translation in Brief

CAR Ts against senescent cells; plus NIH program for ALS, sex-dependent COVID-19 immune responses and more

CAR T liver fibrosis therapy  Memorial Sloan Kettering Cancer Center researchers have generated CAR T cells against PLAUR, which is involved in extracellular matrix remodelling, that could eliminate pathologic senescent cells . Senescent cells have been...
BioCentury | May 21, 2020
Emerging Company Profile

Repertoire bets on both sides of the TCR-antigen coin

Flagship’s Repertoire aims to identify which TCRs and antigens matter in disease and apply those insights to biomarkers and therapies, starting with a cytokine-loaded T cell candidate for cancer. Repertoire Immune Medicines Inc. emerged in...
BioCentury | Mar 13, 2020
Deals

Flagship’s Repertoire combines Cogen, Torque to pick antigens for immunotherapies

By combining TCR-antigen matching company Cogen with T cell therapy play Torque, Flagship Pioneering’s Repertoire Immune Medicines Inc. aims to boost the latter’s ongoing oncology programs while demonstrating clinical proof of concept for the former’s...
BioCentury | Mar 12, 2020
Product Development

With initial PKU trial ‘uninterpretable,’ Rubius turns to cancer, autoimmune diseases

Rubius is throwing in the towel on its first clinical trial to treat phenylketonuria after manufacturing difficulties and a lag in patient recruitment had dogged the study from the beginning. Instead, the red blood cell...
BioCentury | Mar 2, 2020
Finance

Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

Xilio plans to bring its two lead immuno-oncology candidates to clinical proof-of-concept data, as well as advance its earlier stage programs, with a tranched $100.5 million series B. Takeda Ventures Inc. led the financing with...
BioCentury | Feb 6, 2020
Product Development

Early signs CAR NKs could compete with CAR Ts in heme cancers

Early clinical data from CAR NK cells have started to roll in, and hint the modality could compete with CAR T cells on efficacy. Built into CAR NK cells are the benefits of off-the-shelf manufacturing...
BC Extra | Jan 14, 2020
Clinical News

Complete response to NK cell therapy prompts NantKwest to plan pivotal trials

NantKwest is planning registration trials for its off-the-shelf NK cell therapy in triple-negative breast cancer and pancreatic cancer after compassionate use of PD-L1.t-haNK led to a complete response in one patient. The data, reported at...
BC Extra | Dec 10, 2019
Clinical News

Investors reward Fate for off-the-shelf NK data at ASH

Fate’s 41% gain following presentations at ASH solidifies its iPS cell-derived NK platform’s status as the company’s center of gravity. The company is advancing a series of increasingly complex off-the-shelf NK cell therapies, with a...
BC Extra | Nov 11, 2019
Clinical News

Nov. 11 SITC Roundup: Celyad's first clinical data for allogeneic CAR Ts, plus Vaccibody and Nektar

Celyad reports no GvHD, two PRs in allogeneic CAR T trial  Newly presented data from a Phase I trial of an allogeneic CAR T from Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) showed that among 12 patients with...
Items per page:
1 - 10 of 130